Financial Data and Key Metrics Changes - In Q3 2024, net sales were $1.824 billion, an increase of 4% on a reported basis and 4.1% excluding foreign currency impact [25] - Adjusted diluted earnings per share (EPS) was $1.74, compared to $1.65 in the prior year, indicating earnings grew faster than revenue [30] - Free cash flow for the quarter was $310 million, bringing year-to-date free cash flow to $652 million [32] Business Line Data and Key Metrics Changes - The combined knee and hip businesses, referred to as the reconstructed platform, grew in the mid-single-digit range globally, while the head segment delivered upper single-digit growth [9] - The S.E.T. segment grew 7.3%, led by CMFT, sports, and upper extremities, marking the fourth consecutive quarter of at least mid-single-digit growth [29] - The "other" category declined by 9.5%, primarily due to difficult comparisons from the prior year and ERP-related challenges [29] Market Data and Key Metrics Changes - The U.S. business grew by 2%, while international sales grew by 7.1%, with strength across knee and S.E.T. segments [26] - Global knees grew by 5.5%, with U.S. growth at 2.9% and international growth at 9.2% [26] - Global hips grew by 3.7%, with U.S. growth at 4.9% and international growth at 2.4% [27] Company Strategy and Development Direction - The company is focused on three strategic priorities: people and culture, operational excellence, and innovation and diversification [16] - The company plans to maintain mid-single-digit revenue growth and adjusted EPS growth of at least 1.5 times revenue through 2027 [19] - The innovation pipeline includes over 50 meaningful product launches, with a strong emphasis on the hips platform and robotics [11][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resolution of ERP challenges and anticipates returning to normal shipping levels by the end of 2024 [8] - The company expects continued market growth driven by an aging population and technological advancements [10] - Management remains optimistic about 2025, citing new product introductions and the resolution of ERP issues as key factors [42] Other Important Information - The company repurchased approximately $600 million in shares during Q3, with over $850 million repurchased through the end of October [33] - The company updated its 2024 guidance, expecting constant currency revenue growth of 4.25% to 4.75% [34] Q&A Session Summary Question: Why is the guidance cut more than the ERP issue for 2024? - Management indicated a conservative approach due to various factors, including pricing dynamics and recent disruptions [39] Question: What are the updated thoughts on M&A? - Management stated that while they do not need to pursue M&A to maintain growth, they are open to opportunities that make strategic and financial sense [45][46] Question: Can you provide insights into the reconstructive businesses, particularly knees? - Management confirmed recovery from previous supply chain issues and expressed optimism for knee performance moving forward [50] Question: What are the expectations for pricing in the U.S.? - Management noted positive pricing trends and structural improvements leading to better performance [86] Question: What impact is volume-based purchasing in China having? - Management reported that China represents 2% to 3% of global sales and has not significantly impacted revenue expectations [91]

For the quarter ended September 2024, Zimmer Biomet (ZBH) reported revenue of $1.82 billion, up 4% over the same period last year. EPS came in at $1.74, compared to $1.65 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.8 billion, representing a surprise of +1.12%. The company delivered an EPS surprise of -0.57%, with the consensus EPS estimate being $1.75.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.57%. A quarter ago, it was expected that this orthopedic device maker would post earnings of $1.98 per share when it actually produced earnings of $2.01, delivering a surprise of 1.52%. Over the last four quarters ...

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 heather.zoumaslubeski@zimmerbiomet.com david.demartino@zimmerbiomet.com Zach Weiner (908) 591-6955 zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Third Quarter 2024 Financial Results • Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency 1 basis • Third quarter diluted earnings per share were $1.23; adjusted 1 dilute ...

In its upcoming report, Zimmer Biomet (ZBH) is predicted by Wall Street analysts to post quarterly earnings of $1.75 per share, reflecting an increase of 6.1% compared to the same period last year. Revenues are forecasted to be $1.8 billion, representing a year-over-year increase of 2.9%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during ...

Core Insights - Zimmer Biomet Holdings, Inc. is set to launch the Z1 Femoral Hip System for total hip arthroplasty at the 2024 AAHKS annual meeting, showcasing its advanced hip portfolio and enabling technologies [1][4] Group 1: Product Launch and Features - The Z1 Femoral Hip System is a triple-taper femoral system designed to enhance stability and efficiency in total hip arthroplasty, complementing the G7 Acetabular System [1][2] - The Z1 System offers collared and collarless options for cementless applications and includes three distinct neck options to accommodate various patient anatomies [2] - The system is designed to minimize the instrument footprint, thereby reducing processing and sterilization burdens for surgical teams [2] Group 2: Clinical Feedback and Innovations - Initial user feedback from surgeons indicates that the Z1 System is intuitive and versatile, enhancing the surgical experience compared to earlier models [3] - Zimmer Biomet has expanded its hip portfolio through strategic acquisitions, including OrthoGrid Systems, which provides AI-powered surgical assistance applications [3] - The OrthoGrid Hip AI technology offers real-time intra-operative guidance for optimal surgical outcomes, further enhancing the capabilities of the Z1 System [3] Group 3: Upcoming Presentations and Studies - At the AAHKS meeting, Zimmer Biomet will present data from three clinical studies related to hip arthroplasty, focusing on metal ion levels, clinical outcomes, and quality of life correlations [4]

Zimmer Biomet (ZBH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on October 30, 2024, might help the stock move higher if these key numbers are better t ...

Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report third-quarter 2024 results on Oct. 30, before market open. In the last reported quarter, the company's earnings of $2.01 beat the Zacks Consensus Estimate by 1.5%. ZBH beat on earnings in each of the trailing four quarters, the average surprise being 2.84%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. ZBH's Q3 Estimates The Zacks Consensus Estimate for revenues is pegged at $1.81 billion, suggesting a 3.3% rise from the yea ...

Group 1 - Zimmer Biomet Holdings, Inc. will host its third quarter earnings conference call on October 30, 2024, at 8:30 a.m. ET, with a news release available at 6:30 a.m. ET on the same day [1] - The conference call can be accessed via Zimmer Biomet's Investor Relations website and will be available for replay after the call [1] - U.S. and Canada participants can join the call by dialing (888) 204-4368, while international callers should use +1 (323) 994-2093, both requiring conference ID 5103691 [2] Group 2 - Zimmer Biomet is recognized as a global leader in medical technology, focusing on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies [3] - The company has over 90 years of experience and is committed to delivering high-quality solutions to patients and providers, emphasizing a culture of evolution and innovation [4] - Zimmer Biomet operates in over 25 countries and has sales in more than 100 countries, showcasing its extensive global reach [5]

Zimmer Biomet's (ZBH) strategic efforts to drive growth in the Knee business are anchored by four meaningful pillars. The stabilization of the global musculoskeletal market is encouraging for future growth. By expanding its portfolio to include upper and lower joints, the company is enhancing its presence in emerging markets. Meanwhile, a debt-burdened balance sheet and adverse currency movements remain concerns for ZBH's operations. In the past year, this Zacks Rank #3 (Hold) stock has dropped 2.7% in valu ...